Institution
Levanger Hospital
Healthcare•Levanger, Norway•
About: Levanger Hospital is a healthcare organization based out in Levanger, Norway. It is known for research contribution in the topics: Population & Odds ratio. The organization has 140 authors who have published 241 publications receiving 9911 citations.
Topics: Population, Odds ratio, Hazard ratio, Anxiety, Cohort study
Papers published on a yearly basis
Papers
More filters
••
University of Texas Health Science Center at Houston1, Broad Institute2, Harvard University3, University of Wisconsin–Milwaukee4, University of Washington5, Washington University in St. Louis6, University of North Carolina at Chapel Hill7, Icahn School of Medicine at Mount Sinai8, University of Michigan9, Lund University10, University of Leicester11, Queen Mary University of London12, University of Oxford13, University of Milan14, University of Verona15, Merck & Co.16, National Institutes of Health17, Levanger Hospital18, Norwegian University of Science and Technology19, University of Ottawa20, Stanford University21, University of Iowa22, George Washington University23, Umeå University24, University of Dundee25, Cambridge University Hospitals NHS Foundation Trust26, Technische Universität München27, University of Kiel28, University of Lübeck29, University of Bonn30, Group Health Cooperative31, Baylor College of Medicine32, Houston Methodist Hospital33, IMDEA34, Tufts University35, University of Leeds36, King Abdulaziz University37, Wellcome Trust Sanger Institute38, University of Mississippi39, Fred Hutchinson Cancer Research Center40, University of Virginia41, University of Vermont42, Boston University43
TL;DR: Rare mutations that disrupt AP OC3 function were associated with lower levels of plasma triglycerides and APOC3, and carriers of these mutations were found to have a reduced risk of coronary heart disease.
Abstract: Background Plasma triglyceride levels are heritable and are correlated with the risk of coronary heart disease. Sequencing of the protein-coding regions of the human genome (the exome) has the potential to identify rare mutations that have a large effect on phenotype. Methods We sequenced the protein-coding regions of 18,666 genes in each of 3734 participants of European or African ancestry in the Exome Sequencing Project. We conducted tests to determine whether rare mutations in coding sequence, individually or in aggregate within a gene, were associated with plasma triglyceride levels. For mutations associated with triglyceride levels, we subsequently evaluated their association with the risk of coronary heart disease in 110,970 persons. Results An aggregate of rare mutations in the gene encoding apolipoprotein C3 (APOC3) was associated with lower plasma triglyceride levels. Among the four mutations that drove this result, three were loss-of-function mutations: a nonsense mutation (R19X) and two splice-site mutations (IVS2+1G→A and IVS3+1G→T). The fourth was a missense mutation (A43T). Approximately 1 in 150 persons in the study was a heterozygous carrier of at least one of these four mutations. Triglyceride levels in the carriers were 39% lower than levels in noncarriers (P<1×10 − 20 ), and circulating levels of APOC3 in carriers were 46% lower than levels in noncarriers (P = 8×10 − 10 ). The risk of coronary heart disease among 498 carriers of any rare APOC3 mutation was 40% lower than the risk among 110,472 noncarriers (odds ratio, 0.60; 95% confidence interval, 0.47 to 0.75; P = 4×10 − 6 ). Conclusions Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease. (Funded by the National Heart, Lung, and Blood Institute and others.)
877 citations
••
TL;DR: CKD prevalence in Norway was similar to that in the United States, suggesting that lower progression to ESRD rather than a smaller pool of individuals at risk accounts for the lower incidence of E SRD in Norway.
Abstract: ESRD incidence is much lower in Europe compared with the United States. This study investigated whether this reflects a difference in the prevalence of earlier stages of chronic kidney disease (CKD) or other mechanisms. CKD prevalence in Norway was estimated from the population-based Health Survey of Nord-Trondelag County (HUNT II), which included 65,181 adults in 1995 through 1997 (participation rate 70.4%). Data were analyzed using the same methods as two US National Health and Nutrition Examination Surveys in 1988 through 1994 (n = 15,488) and 1999 through 2000 (n = 4101). The primary analysis used gender-specific cutoffs in estimating persistent albuminuria for CKD stages 1 and 2. ESRD rates and other relevant data were extracted from national registries. Total CKD prevalence in Norway was 10.2% (SE 0.5): CKD stage 1 (GFR >90 ml/min per 1.73 m2 and albuminuria), 2.7% (SE 0.3); stage 2 (GFR 60 to 89 ml/min per 1.73 m2 and albuminuria), 3.2% (SE 0.4); stage 3 (GFR 30 to 59 ml/min per 1.73 m2), 4.2% (SE 0.1); and stage 4 (GFR 15 to 29 ml/min per 1.73 m2), 0.2% (SE 0.01). This closely approximates reported US CKD prevalence (11.0% in 1988 through 1994 and 11.7% in 1999 through 2000). The relative risk for progression from CKD stages 3 or 4 to ESRD in US white patients compared with Norwegian patients was 2.5. This was only modestly modified by adjustment for age, gender, and diabetes. Age and GFR at start of dialysis were similar, hypertension and cardiovascular mortality in the populations were comparable, but US white patients were referred later to a nephrologist and had higher prevalence of obesity and diabetes. In conclusion, CKD prevalence in Norway was similar to that in the United States, suggesting that lower progression to ESRD rather than a smaller pool of individuals at risk accounts for the lower incidence of ESRD in Norway.
694 citations
••
TL;DR: This paper performed fine mapping of 39 established type 2 diabetes (T2D) loci in 27,206 cases and 57,574 controls of European ancestry, and identified 49 distinct association signals at these loci including five mapping in or near KCNQ1.
Abstract: We performed fine mapping of 39 established type 2 diabetes (T2D) loci in 27,206 cases and 57,574 controls of European ancestry. We identified 49 distinct association signals at these loci, including five mapping in or near KCNQ1. 'Credible sets' of the variants most likely to drive each distinct signal mapped predominantly to noncoding sequence, implying that association with T2D is mediated through gene regulation. Credible set variants were enriched for overlap with FOXA2 chromatin immunoprecipitation binding sites in human islet and liver cells, including at MTNR1B, where fine mapping implicated rs10830963 as driving T2D association. We confirmed that the T2D risk allele for this SNP increases FOXA2-bound enhancer activity in islet- and liver-derived cells. We observed allele-specific differences in NEUROD1 binding in islet-derived cells, consistent with evidence that the T2D risk allele increases islet MTNR1B expression. Our study demonstrates how integration of genetic and genomic information can define molecular mechanisms through which variants underlying association signals exert their effects on disease.
370 citations
••
TL;DR: In this paper, the authors examined the association of insomnia symptoms with demographic and physical and mental conditions in a large population-based study and found that reporting insomnia symptoms significantly increased the associations with a range of conditions, especially mental conditions, pain conditions with uncertain etiology and, to a lesser extent, chronic pain conditions.
317 citations
••
TL;DR: In this paper, a 4.4-year mortality follow-up of 2,089 men and women without diabetes and treated hypertension, randomly selected from the population-based Nord-Trondelag Health Study (1995 to 1997; n=65,258), was conducted.
271 citations
Authors
Showing all 141 results
Name | H-index | Papers | Citations |
---|---|---|---|
Kristian Hveem | 84 | 328 | 48030 |
Stian Lydersen | 55 | 363 | 13410 |
Steinar Krokstad | 41 | 155 | 14901 |
Håvard Dalen | 31 | 115 | 3572 |
Kirsti Kvaløy | 28 | 63 | 9150 |
Ottar Bjerkeset | 23 | 70 | 2221 |
Hans M. Nordahl | 23 | 75 | 1842 |
Oluf Dimitri Røe | 22 | 68 | 1685 |
Carl G. P. Platou | 21 | 31 | 14135 |
Solfrid Romundstad | 18 | 35 | 2675 |
Ulla Romild | 18 | 31 | 1701 |
Grete Helen Bratberg | 16 | 24 | 2174 |
Birger Henning Endreseth | 15 | 25 | 905 |
Eivind Ness-Jensen | 14 | 56 | 885 |
Tom-Harald Edna | 13 | 27 | 661 |